ANXA5 and coronary artery disorder: Regarding the value of EVs as biomarker for risk prediction and outcomes, circulating levels of CD31-positive, annexin V-positive MPs may also be useful as independent predictors of cardiovascular outcomes, as suggested by findings in 200 patients with stable CAD followed for a mean of 6 years [184].